{"slug":"flt3","tag":"flt3","variants":["flt3"],"description":"No description yet","count":4,"kinds":{"person":2,"biomarker":2},"related":[{"slug":"aml","tag":"aml","shared":2},{"slug":"biomarker","tag":"biomarker","shared":2},{"slug":"cooperative-group","tag":"cooperative-group","shared":1},{"slug":"targeted-therapy","tag":"targeted-therapy","shared":1}],"records":[{"id":"richard-stone","kind":"person","name":"Richard M. Stone","route":"/people/richard-stone/","tldr":"Led RATIFY, the trial that made midostaurin the first targeted therapy added to induction chemotherapy for AML."},{"id":"alexander-perl","kind":"person","name":"Alexander E. Perl","route":"/people/alexander-perl/","tldr":"Led ADMIRAL, which made gilteritinib the standard for relapsed FLT3-mutant AML."},{"id":"flt3-itd","kind":"biomarker","name":"FLT3-ITD (internal tandem duplication)","route":"/biomarkers/flt3-itd/","tldr":"FLT3-ITD is a duplicated stretch of the FLT3 receptor gene found in about a quarter of acute myeloid leukaemias; it makes relapse more likely and is treated with midostaurin, quizartinib or gilteritinib."},{"id":"flt3-tkd","kind":"biomarker","name":"FLT3-TKD (D835 and I836 tyrosine kinase domain mutations)","route":"/biomarkers/flt3-tkd/","tldr":"FLT3-TKD mutations are point changes in the kinase's activation loop, found in about 7 percent of acute myeloid leukaemias. Midostaurin and gilteritinib labels cover them; quizartinib's does not."}]}